Skip to main content
SpringerLink
Log in

Mantle Cell Lymphoma: Current Concept in Biology and Treatment

  • Chapter
Hodgkin’s and Non-Hodgkin’s Lymphoma

Part of the book series: Cancer Treatment and Research ((CTAR,volume 131))

Abstract

Mantle cell lymphoma (MCL) is a distinct subtype and accounts for approximately 5–10% of non-Hodgkin’s lymphomas. The tumor cells are characterized by CD5-positive, CD23-negative follicular mantle B cells with typical t(11; 14)(q13;q32) translocation and cyclin Dl protein over-expression. Four histological subtypes of MCL have been described which include mantle zone, nodular, diffuse, and blastoid forms. MCL commonly occurs in elderly patients with disseminated disease involving lymph nodes, spleen, bone marrow, blood, and the gastrointestinal system. The clinical course is typically more aggressive than indolent lymphomas with median survival of 3–4 years.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
eBook
USD 16.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

7. References

  1. Harris, N.L., Jaffe, E.S., Stein, H., Banks, P.M., Chan, J.K., Cleary, M.L., Delsol, G., De Wolf-Peeters, C., Falini, B. and Gatter, K.C., A revised european-american classification of lymphoid neoplasms: A proposal from the international lymphoma study group. [see comment], [review] [296 refs]. Blood., 1994. 84(5): p. 1361–1392.

    PubMed  CAS  Google Scholar 

  2. Braylan, R.C., Jaffe, E.S. and Berard, C.W., Malignant lymphomas: Current classification and new observations, [review] [149 refs]. Pathology Annual, 1975. 10: p. 213–270.

    PubMed  CAS  Google Scholar 

  3. Anonymous, National cancer institute sponsored study of classifications of non-hodgkin’s lymphomas: Summary and description of a working formulation for clinical usage. The non-hodgkin’s lymphoma pathologic classification project. Cancer, 1982. 49(10): p. 2112–2135.

    Google Scholar 

  4. Anderson, J.R., Armitage, J.O. and Weisenburger, D.D., Epidemiology of the non-hodgkin’s lymphomas: Distributions of the major subtypes differ by geographic locations. Non-hodgkin’s lymphoma classification project. Annals of Oncology, 1998. 9(7): p. 717–720.

    Article  PubMed  CAS  Google Scholar 

  5. Weisenburger, D.D. and Armitage, J.O., Mantle cell lymphoma— an entity comes of age. [see comment], [review] [119 refs]. Blood, 1996. 87(11): p. 4483–4494.

    PubMed  CAS  Google Scholar 

  6. Harris, N.L., Jaffe, E.S., Diebold, J., Flandrin, G., Muller-Hermelink, H.K., Vardiman, J., Lister, T.A. and Bloomfield, C.D., World health organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: Report of the clinical advisory committee meeting-airlie house, Virginia, november 1997. [see comment]. Journal of Clinical Oncology., 1999. 17(12): p. 3835–3849.

    PubMed  CAS  Google Scholar 

  7. Weisenburger, D.D., Mantle cell lymphoma, in Neoplastic hematopathology, D. M. Knowles, Editor. 2001, Lippincott Williams & Wilkins: Philadelphia, p. 789–803.

    Google Scholar 

  8. Harris, N.L., Nadler, L.M. and Bhan, A.K., Immunohistologic characterization of two malignant lymphomas of germinal center type (centroblastic/centrocytic and centrocytic) with monoclonal antibodies. Follicular and diffuse lymphomas of small-cleaved-cell type are related but distinct entities. American Journal of Pathology, 1984. 117(2): p. 262–272.

    PubMed  CAS  Google Scholar 

  9. Zukerberg, L.R., Medeiros, L.J., Ferry, J.A. and Harris, N.L., Diffuse low-grade b-cell lymphomas. Four clinically distinct subtypes defined by a combination of morphologic and immunophenotypic features, [see comment]. American Journal of Clinical Pathology, 1993. 100(4): p. 373–385.

    PubMed  CAS  Google Scholar 

  10. Zukerberg, L.R., Yang, W.I., Arnold, A. and Harris, N.L., Cyclin dl expression in non-hodgkin’s lymphomas. Detection by immunohistochemistry. American Journal of Clinical Pathology, 1995. 103(6): p. 756–760.

    PubMed  CAS  Google Scholar 

  11. Swerdlow, S.H. and Williams, M.E., From centrocytic to mantle cell lymphoma: A clinicopathologic and molecular review of 3 decades. [review] [134 refs]. Human Pathology, 2002. 33(1): p. 7–20.

    Article  PubMed  CAS  Google Scholar 

  12. Yatabe, Y., Suzuki, R., Tobinai, K., Matsuno, Y., Ichinohasama, R., Okamoto, M., Yamaguchi, M., Tamaru, J., Uike, N., Hashimoto, Y., Morishima, Y., Suchi, T., Seto, M. and Nakamura, S., Significance of cyclin dl overexpression for the diagnosis of mantle cell lymphoma: A clinicopathologic comparison of cyclin dl-positive mcl and cyclin dl-negative mcl-like b-cell lymphoma. Blood, 2000. 95(7): p. 2253–2261.

    PubMed  CAS  Google Scholar 

  13. Rosenberg, C.L., Wong, E., Petty, E.M., Bale, A.E., Tsujimoto, Y., Harris, N.L. and Arnold, A., Pradl, a candidate bcl1 oncogene: Mapping and expression in centrocytic lymphoma. Proceedings of the National Academy of Sciences of the United States of America, 1991. 88(21): p. 9638–9642.

    Article  PubMed  CAS  Google Scholar 

  14. Williams, M.E. and Swerdlow, S.H., Cyclin dl overexpression in non-hodgkin’s lymphoma with chromosome 11 bcl-1 rearrangement. Annals of Oncology, 1994. 1: p. 71–73.

    Google Scholar 

  15. Bodrug, S.E., Warner, B.J., Bath, M.L., Lindeman, G.J., Harris, A.W. and Adams, J.M., Cyclin dl transgene impedes lymphocyte maturation and collaborates in lymphomagenesis with the myc gene. EMBO Journal, 1994. 13(9): p. 2124–2130.

    PubMed  CAS  Google Scholar 

  16. Lovec, H., Grzeschiczek, A., Kowalski, M.B. and Moroy, T., Cyclin dl/bcl-1 cooperates with myc genes in the generation of b-cell lymphoma in transgenic mice. EMBO Journal, 1994. 13(15): p. 3487–3495.

    PubMed  CAS  Google Scholar 

  17. Au, W.Y., Gascoyne, R.D., Viswanatha, D.S., Connors, J.M., Klasa, R.J. and Horsman, D.E., Cytogenetic analysis in mantle cell lymphoma: A review of 214 cases. Leukemia & Lymphoma, 2002. 43(4): p. 783–791.

    Article  Google Scholar 

  18. Dreyling, M.H., Bullinger, L., Ott, G., Stilgenbauer, S., Muller-Hermelink, H.K., Bentz, M., Hiddemann, W. and Dohner, H., Alterations of the cyclin dl/p16-prb pathway in mantle cell lymphoma. Cancer Research, 1997. 57(20): p. 4608–4614.

    PubMed  CAS  Google Scholar 

  19. Pinyol, M., Hernandez, L., Cazorla, M., Balbin, M., Jares, P., Fernandez, P.L., Montserrat, E., Cardesa, A., Lopez-Otin, C. and Campo, E., Deletions and loss of expression of pl6ink4a and p21wafl genes are associated with aggressive variants of mantle cell lymphomas. Blood, 1997. 89(1): p. 272–280.

    PubMed  CAS  Google Scholar 

  20. Quintanilla-Martinez, L., Davies-Hill, T., Fend, F., Calzada-Wack, J., Sorbara, L., Campo, E., Jaffe, E.S. and Raffeld, M., Sequestration of p27kipl protein by cyclin dl in typical and blastic variants of mantle cell lymphoma (mcl): Implications for pathogenesis. Blood, 2003. 101(8): p. 3181–3187.

    Article  PubMed  CAS  Google Scholar 

  21. Greiner, T.C., Moynihan, M.J., Chan, W.C., Lytle, D.M., Pedersen, A., Anderson, J.R. and Weisenburger, D.D., P53 mutations in mantle cell lymphoma are associated with variant cytology and predict a poor prognosis. Blood, 1996. 87(10): p. 4302–4310.

    PubMed  CAS  Google Scholar 

  22. Nagy, B., Lundan, T., Larramendy, M.L., Aalto, Y., Zhu, Y., Niini, T., Edgren, H., Ferrer, A., Vilpo, J., Elonen, E., Vettenranta, K., Franssila, K. and Knuutila, S., Abnormal expression of apoptosis-related genes in haematological malignancies: Overexpression of myc is poor prognostic sign in mantle cell lymphoma. British Journal of Haematology, 2003. 120(3): p. 434–441.

    Article  PubMed  CAS  Google Scholar 

  23. Hofmann, W.K., De Vos, S., Tsukasaki, K., Wachsman, W., Pinkus, G.S., Said, J.W. and Koeffler, H.P., Altered apoptosis pathways in mantle cell lymphoma detected by oligonucleotide microarray. Blood, 2001. 98(3): p. 787–794.

    Article  PubMed  CAS  Google Scholar 

  24. De Leeuw, R.J., Davies, J.J., Rosenwald, A., Bebb, G., Gascoyne, R.D., Dyer, M.J., Staudt, L.M., Martinez-Climent, J.A. and Lam, W.L., Comprehensive whole genome array cgh profiling of mantle cell lymphoma model genomes. Human Molecular Genetics, 1827. 13(17): p. 1827–1837.

    Article  Google Scholar 

  25. Tagawa, H., Karnan, S., Suzuki, R., Matsuo, K., Zhang, X., Ota, A., Morishima, Y., Nakamura, S. and Seto, M., Genome-wide array-based cgh for mantle cell lymphoma: Identification of homozygous deletions of the proapoptotic gene bim. Oncogene, 1348. 24(8): p. 1348–1358.

    Article  Google Scholar 

  26. Hunter, T. and Pines, J., Cyclins and cancer. Ii: Cyclin d and cdk inhibitors come of age. [see comment], [review] [152 refs]. Cell, 1994. 79(4): p. 573–582.

    Article  PubMed  CAS  Google Scholar 

  27. Xiao, Z.X., Ginsberg, D., Ewen, M. and Livingston, D.M., Regulation of the retinoblastoma protein-related protein p107 by gl cyclin-associated kinases. Proceedings of the National Academy of Sciences of the United States of America, 1996. 93(10): p. 4633–4637.

    Article  PubMed  CAS  Google Scholar 

  28. Bergsagel, P.L. and Kuehl, W.M., Critical roles for immunoglobulin trans locations and cyclin d dysregulation in multiple myeloma. [review] [30 refs]. Immunological Reviews, 2003. 194: p. 96–104.

    Article  PubMed  CAS  Google Scholar 

  29. Athanasiou, E., Kotoula, V., Hytiroglou, P., Kouidou, S., Kaloutsi, V. and Papadimitriou, C.S., In situ hybridization and reverse transcription-polymerase chain reaction for cyclin dl mrna in the diagnosis of mantle cell lymphoma in paraffin-embedded tissues. Modern Pathology, 2001. 14(2): p. 62–71.

    Article  PubMed  CAS  Google Scholar 

  30. Bijwaard, K.E., Aguilera, N.S., Monczak, Y., Trudel, M., Taubenberger, J.K. and Lichy, J.H., Quantitative real-time reverse transcription-pcr assay for cyclin dl expression: Utility in the diagnosis of mantle cell lymphoma. Clinical Chemistry, 2001. 47(2): p. 195–201.

    PubMed  CAS  Google Scholar 

  31. Elnenaei, M.O., Jadayel, D.M., Matutes, E., Morilla, R., Owusu-Ankomah, K., Atkinson, S., Titley, I., Mandala, E.M. and Catovsky, D., Cyclin dl by flow cytometry as a useful tool in the diagnosis of b-cell malignancies. Leukemia Research, 2001. 25(2): p. 115–123.

    Article  PubMed  CAS  Google Scholar 

  32. Rimokh, R., Berger, F., Bastard, C., Klein, B., French, M., Archimbaud, E., Rouault, J.P., Santa Lucia, B., Duret, L., Vuillaume, M. and Et Al., Rearrangement of ccndl (bcl1/prad1) 3′ untranslated region in mantle-cell lymphomas and t(11q13)-associated leukemias. Blood, 1994. 83(12): p. 3689–3696.

    PubMed  CAS  Google Scholar 

  33. Hernandez, L., Hernandez, S., Bea, S., Pinyol, M., Ferrer, A., Bosch, F., Nadal, A., Fernandez, P.L., Palacin, A., Montserrat, E. and Campo, E., C-myc mrna expression and genomic alterations in mantle cell lymphomas and other nodal non-hodgkin’s lymphomas. Leukemia, 1999. 13(12): p. 2087–2093.

    Article  PubMed  CAS  Google Scholar 

  34. Koduru, P.R., Zariwala, M., Soni, M., Gong, J.Z., Xiong, Y. and Broome, J.D., Deletion of cyclin-dependent kinase 4 inhibitor genes pl5 and pl6 in non-hodgkin’s lymphoma. Blood, 1995. 86(8): p. 2900–2905.

    PubMed  CAS  Google Scholar 

  35. Louie, D.C., Offit, K., Jaslow, R., Parsa, N.Z., Murty, V.V., Schluger, A. and Chaganti, R.S., P53 overexpression as a marker of poor prognosis in mantle cell lymphomas with t(11;14)(q13;q32). Blood, 1995. 86(8): p. 2892–2899.

    PubMed  CAS  Google Scholar 

  36. Stilgenbauer, S., Schaffner, C., Winkler, D., Ott, G., Leupolt, E., Bentz, M., Moller, P., Muller-Hermelink, H.K., James, M.R., Lichter, P. and Dohner, H., The atm gene in the pathogenesis of mantle-cell lymphoma. Annals of Oncology, 2000. 1: p. 127–130.

    Article  Google Scholar 

  37. Schaffner, C., Idler, I., Stilgenbauer, S., Dohner, H. and Lichter, P., Mantle cell lymphoma is characterized by inactivation of the atm gene. Proceedings of the National Academy of Sciences of the United States of America, 2000. 97(6): p. 2773–2778.

    Article  PubMed  CAS  Google Scholar 

  38. Fang, N.Y., Greiner, T.C., Weisenburger, D.D., Chan, W.C., Vose, J.M., Smith, L.M., Armitage, J.O., Mayer, R.A., Pike, B.L., Collins, F.S. and Hacia, J.G., Oligonucleotide microarrays demonstrate the highest frequency of atm mutations in the mantle cell subtype of lymphoma. Proceedings of the National Academy of Sciences of the United States of America, 2003. 100(9): p. 5372–5377.

    Article  PubMed  CAS  Google Scholar 

  39. Narducci, M.G., Pescarmona, E., Lazzeri, C., Signoretti, S., Lavinia, A.M., Remotti, D., Scala, E., Baroni, C.D., Stoppacciaro, A., Croce, CM. and Russo, G., Regulation of tcll expression in b-and t-cell lymphomas and reactive lymphoid tissues. Cancer Research, 2000. 60(8): p. 2095–2100.

    PubMed  CAS  Google Scholar 

  40. Mertens, D., Wolf, S., Bullinger, L., Ohl, S., Schaffner, C., Dohner, H., Stilgenbauer, S. and Lichter, P., Bcmsun, a candidate gene for b-cell chronic lymphocytic leukemia and mantle-cell lymphoma, has an independently expressed homolog on 1p22–p31, bcmsun-like. International Journal of Cancer, 2000. 88(5): p. 692–697.

    Article  CAS  Google Scholar 

  41. Capello, D., Vitolo, U., Pasqualucci, L., Quattrone, S., Migliaretti, G., Fassone, L., Ariatti, C., Vivenza, D., Gloghini, A., Pastore, C., Lanza, C., Nomdedeu, J., Botto, B., Freilone, R., Buonaiuto, D., Zagonel, V., Gallo, E., Palestro, G., Saglio, G., Dalla-Favera, R., Carbone, A. and Gaidano, G., Distribution and pattern of bcl-6 mutations throughout the spectrum of b-cell neoplasia. Blood, 2000. 95(2): p. 651–659.

    PubMed  CAS  Google Scholar 

  42. Gordon, J., Cd40 and its ligand: Central players in b lymphocyte survival, growth, and differentiation. [review] [35 refs]. Blood Reviews, 1995. 9(1): p. 53–56.

    Article  PubMed  CAS  Google Scholar 

  43. Wang, H., Grand, R.J., Milner, A.E., Armitage, R.J., Gordon, J. and Gregory, C.D., Repression of apoptosis in human b-lymphoma cells by cd40-ligand and bcl-2: Relationship to the cell-cycle and role of the retinoblastoma protein. Oncogene, 1996. 13(2): p. 373–379.

    PubMed  CAS  Google Scholar 

  44. Andersen, N.S., Larsen, J.K., Christiansen, J., Pedersen, L.B., Christophersen, N.S., Geisler, C.H. and Jurlander, J., Soluble cd40 ligand induces selective proliferation of lymphoma cells inprimary mantle cell lymphoma cell cultures. Blood, 2000. 96(6): p. 2219–2225.

    PubMed  CAS  Google Scholar 

  45. Castillo, R., Mascarenhas, J., Telford, W., Chadburn, A., Friedman, S.M. and Schattner, E.J., Proliferative response of mantle cell lymphoma cells stimulated by cd40 ligation and il-4. Leukemia, 2000. 14(2): p. 292–298.

    Article  PubMed  CAS  Google Scholar 

  46. Visser, H.P., Tewis, M., Willemze, R. and Kluin-Nelemans, J.C., Mantle cell lymphoma proliferates upon il-10 in the cd40 system. Leukemia, 1483. 14(8): p. 1483–1489.

    Google Scholar 

  47. Rosenwald, A., Wright, G., Wiestner, A., Chan, W.C., Connors, J.M., Campo, E., Gascoyne, R.D., Grogan, T.M., Muller-Hermelink, H.K., Smeland, E.B., Chiorazzi, M., Giltnane, J.M., Hurt, E.M., Zhao, H., Averett, L., Henrickson, S., Yang, L., Powell, J., Wilson, W.H., Jaffe, E.S., Simon, R., Klausner, R.D., Montserrat, E., Bosch, F., Greiner, T.C., Weisenburger, D.D., Sanger, W.G., Dave, B.J., Lynch, J.C., Vose, J., Armitage, J.O., Fisher, R.I., Miller, T.P., Leblanc, M., Ott, G., Kvaloy, S., Holte, H., Delabie, J. and Staudt, L.M., The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma. [see comment]. Cancer Cell, 2003. 3(2): p. 185–197.

    Article  PubMed  CAS  Google Scholar 

  48. Thieblemont, C., Nasser, V., Felman, P., Leroy, K., Gazzo, S., Callet-Bauchu, E., Loriod, B., Granjeaud, S., Gaulard, P., Haioun, C., Traverse-Glehen, A., Baseggio, L., Bertucci, F., Birnbaum, D., Magrangeas, F., Minvielle, S., Avet-Loiseau, H., Salles, G., Coiffier, B., Berger, F. and Houlgatte, R., Small lymphocytic lymphoma, marginal zone b-cell lymphoma, and mantle cell lymphoma exhibit distinct gene-expression profiles allowing molecular diagnosis. Blood, 2004. 103(7): p. 2727–2737.

    Article  PubMed  CAS  Google Scholar 

  49. Ek, S., Hogerkorp, C.M., Dictor, M., Ehinger, M. and Borrebaeck, C.A., Mantle cell lymphomas express a distinct genetic signature affecting lymphocyte trafficking and growth regulation as compared with subpopulations of normal human b cells. Cancer Research, 2002. 62(15): p. 4398–4405.

    PubMed  CAS  Google Scholar 

  50. Samaha, H., Dumontet, C., Ketterer, N., Moullet, I., Thieblemont, C., Bouafia, F., Callet-Bauchu, E., Felman, P., Berger, F., Salles, G. and Coiffier, B., Mantle cell lymphoma: A retrospective study of 121 cases, [review] [44 refs]. Leukemia., 1998. 12(8): p. 1281–1287.

    Article  PubMed  CAS  Google Scholar 

  51. Weisenburger, D.D., Vose, J.M., Greiner, T.C., Lynch, J.C., Chan, W.C., Bierman, P.J., Dave, B.J., Sanger, W.G. and Armitage, J.O., Mantle cell lymphoma. A clinicopathologic study of 68 cases from the nebraska lymphoma study group. [review] [54 refs]. American Journal of Hematology., 2000. 64(3): p. 190–196.

    Article  PubMed  CAS  Google Scholar 

  52. Majlis, A., Pugh, W.C., Rodriguez, M.A., Benedict, W.F. and Cabanillas, F., Mantle cell lymphoma: Correlation of clinical outcome and biologic features with three histologic variants. Journal of Clinical Oncology, 1664. 15(4): p. 1664–1671.

    Google Scholar 

  53. Geissmann, F., Ruskone-Fourmestraux, A., Hermine, O., Bourquelot, P., Belanger, C., Audouin, J., Delmer, A., Macintyre, E.A., Varet, B. and Brousse, N., Homing receptor alpha4beta7 integrin expression predicts digestive tract involvement in mantle cell lymphoma. American Journal of Pathology, 1701. 153(6): p. 1701–1705.

    Google Scholar 

  54. Chiarle, R., Budel, L.M., Skolnik, J., Frizzera, G., Chilosi, M., Corato, A., Pizzolo, G., Magidson, J., Montagnoli, A., Pagano, M., Maes, B., De Wolf-Peeters, C. and Inghirami, G., Increased proteasome degradation of cyclin-dependent kinase inhibitor p27 is associated with a decreased overall survival in mantle cell lymphoma. Blood, 2000. 95(2): p. 619–626.

    PubMed  CAS  Google Scholar 

  55. Fisher, R.I., Dahlberg, S., Nathwani, B.N., Banks, P.M., Miller, T.P. and Grogan, T.M., A clinical analysis of two indolent lymphoma entities: Mantle cell lymphoma and marginal zone lymphoma (including the mucosa-associated lymphoid tissue and monocytoid b-cell subcategories): A southwest oncology group study. Blood, 1075. 85(4): p. 1075–1082.

    Google Scholar 

  56. Meusers, P., Engelhard, M., Bartels, H., Binder, T., Fulle, H.H., Gorg, K., Gunzer, U., Havemann, K., Kayser, W., Konig, E. and Et Al., Multicentre randomized therapeutic trial for advanced centrocytic lymphoma: Anthracycline does not improve the prognosis. Hematological Oncology, 1989. 7(5): p. 365–380.

    Article  PubMed  CAS  Google Scholar 

  57. Zucca, E., Roggero, E., Pinotti, G., Pedrinis, E., Cappella, C., Venco, A. and Cavalli, F., Patterns of survival in mantle cell lymphoma. Annals of Oncology, 1995. 6(3): p. 257–262.

    PubMed  CAS  Google Scholar 

  58. Nickenig, C., Dreyling, M., Schiegnitz, E., Pfreundschuh, M., Truemper, L.H., Reiser, M., Wandt, H., Lengfelder, E., Ludwig, W., Berdel, W.E., Metzner, B., Hess, G., Forstpointner, R., Parwaresch, R., Hasford, J., Unterhalt, M. and Hiddemann, W., Chop improves response rates but not overall survival in follicular and mantle cell lymphoma (mcl)-results of a randomized trial of the german low grade lymphoma study group (glsg) [abstract]. Blood, 2004. 104: p. 611a.

    Google Scholar 

  59. Khouri, I.F., Romaguera, J., Kantarjian, H., Palmer, J.L., Pugh, W.C., Korbling, M., Hagemeister, F., Samuels, B., Rodriguez, A., Giralt, S., Younes, A., Przepiorka, D., Claxton, D., Cabanillas, F. and Champlin, R., Hyper-cvad and high-dose methotrexate/cytarabine followed by stem-cell transplantation: An active regimen for aggressive mantle-cell lymphoma. Journal of Clinical Oncology., 1998. 16(12): p. 3803–3809.

    PubMed  CAS  Google Scholar 

  60. Meusers, P. and Hense, J., Management of mantle cell lymphoma. [review] [91 refs]. Annals of Hematology, 1999. 78(11): p. 485–494.

    Article  PubMed  CAS  Google Scholar 

  61. Foran, J.M., Rohatiner, A.Z., Coiffier, B., Barbui, T., Johnson, S.A., Hiddemann, W., Radford, J.A., Norton, A.J., Tollerfield, S.M., Wilson, M.P. and Lister, T.A., Multicenter phase ii study of fludarabine phosphate for patients with newly diagnosed lymphoplasmacytoid lymphoma, waldenstrom’s macroglobulinemia, and mantle-cell lymphoma. Journal of Clinical Oncology, 1999. 17(2): p. 546–553.

    PubMed  CAS  Google Scholar 

  62. Zinzani, P.L., Magagnoli, M., Moretti, L., De Renzo, A., Battista, R., Zaccaria, A., Guardigni, L., Mazza, P., Marra, R., Ronconi, F., Lauta, V.M., Bendandi, M., Gherlinzoni, F., Gentilini, P., Ciccone, F., Cellini, C., Stefoni, V., Ricciuti, F., Gobbi, M. and Tura, S., Randomized trial of fludarabine versus fludarabine and idarubicin as frontline treatment in patients with indolent or mantle-cell lymphoma. Journal of Clinical Oncology, 2000. 18(4): p. 773–779.

    PubMed  CAS  Google Scholar 

  63. Coleman, M., Leonard, J.P., Lee, C. and Al., E., The pep-c (c3) oral combination chemotherapy regimen for refractory / relapsed lymphoma: Daily prednisone, etoposide, procarbazine and cyclophosphamide. Blood., 1999. 94: p. 94a.

    Google Scholar 

  64. Kaufmann, H., Raderer, M., Wohrer, S., Puspok, A., Bankier, A., Zielinski, C., Chott, A. and Drach, J., Antitumor activity of rituximab plus thalidomide in patients with relapsed/refractory mantle cell lymphoma. Blood, 2004. 104(8): p. 2269–2271.

    Article  PubMed  CAS  Google Scholar 

  65. Foran, J.M., Rohatiner, A.Z., Cunningham, D., Popescu, R.A., Solal-Celigny, P., Ghielmini, M., Coiffier, B., Johnson, P.W., Gisselbrecht, C., Reyes, F., Radford, J.A., Bessell, E.M., Souleau, B., Benzohra, A. and Lister, T.A., European phase ii study of rituximab (chimeric anti-cd20 monoclonal antibody) for patients with newly diagnosed mantle-cell lymphoma and previously treated mantle-cell lymphoma, immunocytoma, and small b-cell lymphocytic lymphoma. [erratum appears in j clin oncol 2000 may; 18(9):2006]. Journal of Clinical Oncology, 2000. 18(2): p. 317–324.

    PubMed  CAS  Google Scholar 

  66. Foran, J.M., Cunningham, D., Coiffier, B., Solal-Celigny, P., Reyes, F., Ghielmini, M., Johnson, P.W., Gisselbrecht, C., Bradburn, M., Matthews, J. and Lister, T.A., Treatment of mantle-cell lymphoma with rituximab (chimeric monoclonal anti-cd20 antibody): Analysis of factors associated with response. Annals of Oncology, 2000. 1: p. 117–121.

    Article  Google Scholar 

  67. Howard, O.M., Gribben, J.G., Neuberg, D.S., Grossbard, M., Poor, C., Janicek, M.J. and Shipp, M. A., Rituximab and chop induction therapy for newly diagnosed mantle-cell lymphoma: Molecular complete responses are not predictive of progression-free survival. Journal of Clinical Oncology., 2002. 20(5): p. 1288–1294.

    Article  PubMed  CAS  Google Scholar 

  68. Lenz, G., Dreyling, M., Hoster, E., Wormann, B., Duhrsen, U., Metzner, B., Eimermacher, H., Neubauer, A., Wandt, H., Steinhauer, H., Martin, S., Heidemann, E., Aldaoud, A., Parwaresch, R., Hasford, J., Unterhalt, M. and Hiddemann, W., Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: Results of a prospective randomized trial of the german low grade lymphoma study group (glsg). Journal of Clinical Oncology, 2005. 23(9): p. 1984–1992.

    Article  PubMed  CAS  Google Scholar 

  69. Romaguera, J., Fayad, L., Rodriguez, M.A., Hagemeister, F., Pro, B., Mclaughlin, P., Younes, A., Samaniego, F., Goy, A., Sarris, A.H., Dang, N.H., Medeiros, L.J., Katz, R., Gagneja, H., Samuels, B. and Cabanillas, F., Rituximab plus hypercvad (r-hcvad) alternating with rituximab plus high-dose methotrexate-cytarabine (r-m/a) in untreated mantle cell lymphoma (mcl): Prolonged follow-up confirms high rates of failure-free survival (ffs) and overall survival (os) [abstract]. Blood, 2004. 104: p. 128a.

    Article  Google Scholar 

  70. Gopal, A.K., Rajendran, J.G., Petersdorf, S.H., Maloney, D.G., Eary, J.F., Wood, B.L., Gooley, T.A., Bush, S.A., Durack, L.D., Martin, P.J., Matthews, D.C., Appelbaum, F.R., Bernstein, I.D. and Press, O.W., High-dose chemo-radioimmunotherapy with autologous stem cell support for relapsed mantle cell lymphoma. Blood, 2002. 99(9): p. 3158–3162.

    Article  PubMed  CAS  Google Scholar 

  71. Josting, A., Reiser, M., Wickramanayake, P.D., Rueffer, U., Draube, A., Sohngen, D., Tesch, H., Wolf, J., Diehl, V. and Engert, A., Dexa-beam: An effective regimen for cytoreduction prior to high-dose chemotherapy with autologous stem cell support for patients with relapsed/refractory mantle-cell lymphoma. Leukemia & Lymphoma, 2000. 37(1–2): p. 185–187.

    CAS  Google Scholar 

  72. Haas, R., Brittinger, G., Meusers, P., Murea, S., Goldschmidt, H., Wannenmacher, M. and Hunstein, W., Myeloablative therapy with blood stem cell transplantation is effective in mantle cell lymphoma. Leukemia, 1975. 10(12): p. 1975–1979.

    Google Scholar 

  73. Freedman, A.S., Neuberg, D., Gribben, J.G., Mauch, P., Soiffer, R.J., Fisher, D.C., Anderson, K.C., Andersen, N., Schlossman, R., Kroon, M., Ritz, J., Aster, J. and Nadler, L.M., High-dose chemoradiotherapy and anti-b-cell monoclonal antibody-purged autologous bone marrow transplantation in mantle-cell lymphoma: No evidence for long-term remission. [see comment]. Journal of Clinical Oncology., 1998. 16(1): p. 13–18.

    PubMed  CAS  Google Scholar 

  74. Vose, J.M., Bierman, P.J., Weisenburger, D.D., Lynch, J.C., Bociek, Y., Chan, W.C., Greiner, T.C. and Armitage, J.O., Autologous hematopoietic stem cell transplantation for mantle cell lymphoma. Biology of Blood & Marrow Transplantation, 2000. 6(6): p. 640–645.

    Article  CAS  Google Scholar 

  75. Vandenberghe, E., Ruiz De Elvira, C., Loberiza, F.R., Conde, E., Lopez-Guillermo, A., Gisselbrecht, C., Guilhot, F., Vose, J.M., Van Biesen, K., Rizzo, J.D., Weisenburger, D.D., Isaacson, P., Horowitz, M.M., Goldstone, A.H., Lazarus, H.M. and Schmitz, N., Outcome of autologous transplantation for mantle cell lymphoma: A study by the european blood and bone marrow transplant and autologous blood and marrow transplant registries. British Journal of Haematology, 2003. 120(5): p. 793–800.

    Article  PubMed  Google Scholar 

  76. Dreyling, M., Lenz, G., Schiegnitz, E., Van Hoof, A., Gisselbrecht, C. and Al., E., Early consolidation with myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression-free survival in mantle cell lymphoma-long term follow up of a prospective randomized trial of the european mcl network [abstract]. Blood, 2004. 104: p. 7a.

    Article  Google Scholar 

  77. Magni, M., Di Nicola, M., Devizzi, L., Matteucci, P., Lombardi, F., Gandola, L., Ravagnani, F., Giardini, R., Dastoli, G., Tarella, C., Piled, A., Bonadonna, G. and Gianni, A.M., Successful in vivo purging of cd34-containing peripheral blood harvests in mantle cell and indolent lymphoma: Evidence for a role of both chemotherapy and rituximab infusion. Blood, 2000. 96(3): p. 864–869.

    PubMed  CAS  Google Scholar 

  78. Gianni, A.M., Magni, M., Martelli, M., Di Nicola, M., Carlo-Stella, C., Pilotti, S., Rambaldi, A., Cortelazzo, S., Patti, C., Parvis, G., Benedetti, F., Capria, S., Corradini, P., Tarella, C. and Barbui, T., Long-term remission in mantle cell lymphoma following high-dose sequential chemotherapy and in vivo rituximab-purged stem cell autografting (r-hds regimen). Blood, 2003. 102(2): p. 749–755.

    Article  PubMed  CAS  Google Scholar 

  79. Geisler, C.H., Elonen, E., Kolstad, A., Laurell, A. and Al., E., Nordic mantle cell lymphoma (mcl) project: Prolonged follow-up of 86 patients treated with beam/beac + pbsct confirms that addition of high-dose ara-c and rituximab to chop induction + in-vivo purging with rituximab increases clinical and molecular response rates, pcr-neg. Grafts, failure-free, relapse-free and overall survival [abstract]. Blood, 2004. 104: p. 8a.

    Article  Google Scholar 

  80. Khouri, I.F., Lee, M.S., Romaguera, J., Mirza, N., Kantarjian, H., Korbling, M., Albitar, M., Giralt, S., Samuels, B., Anderlini, P., Rodriguez, J., Von Wolff, B., Gajewski, J., Cabanillas, F. and Champlin, R., Allogeneic hematopoietic transplantation for mantle-cell lymphoma: Molecular remissions and evidence of graft-versus-malignancy. Annals of Oncology, 1293. 10(11): p. 1293–1299.

    Article  Google Scholar 

  81. Kroger, N., Hoffknecht, M., Kruger, W., Zeller, W., Renges, H., Stute, N., Zschaber, R. and Zander, A.R., Allogeneic bone marrow transplantation for refractory mantle cell lymphoma. Annals of Hematology, 2000. 79(10): p. 578–580.

    Article  PubMed  CAS  Google Scholar 

  82. Martinez, C., Carreras, E., Rovira, M., Urbano-Ispizua, A., Esteve, J., Perales, M., Fernandez, F. and Montserrat, E., Patients with mantle-cell lymphoma relapsing after autologous stem cell transplantation may be rescued by allogeneic transplantation. Bone Marrow Transplantation, 2000. 26(6): p. 677–679.

    Article  PubMed  CAS  Google Scholar 

  83. Khouri, I.F., Lee, M.S., Saliba, R.M., Jun, G., Fayad, L., Younes, A., Pro, B., Acholonu, S., Mclaughlin, P., Katz, R.L. and Champlin, R.E., Nonablative allogeneic stem-cell transplantation for advanced/recurrent mantle-cell lymphoma. Journal of Clinical Oncology, 2003. 21(23): p. 4407–4412.

    Article  PubMed  CAS  Google Scholar 

  84. Maris, M.B., Sandmaier, B.M., Storer, B.E., Chauncey, T., Stuart, M.J., Maziarz, R.T., Agura, E., Langston, A.A., Pulsipher, M., Storb, R. and Maloney, D.G., Allogeneic hematopoietic cell transplantation after fludarabine and 2 gy total body irradiation for relapsed and refractory mantle cell lymphoma [abstract]. Blood, 2004. 104: p. 809a.

    Article  Google Scholar 

  85. Orlowski, R.Z., Stinchcombe, T.E., Mitchell, B.S., Shea, T.C., Baldwin, A.S., Stahl, S., Adams, J., Esseltine, D.L., Elliott, P.J., Pien, C.S., Guerciolini, R., Anderson, J.K., Depcik-Smith, N.D., Bhagat, R., Lehman, M.J., Novick, S.C., O’connor, O.A. and Soignet, S.L., Phase i trial of the proteasome inhibitor ps-341 inpatients with refractory hematologic malignancies. Journal of Clinical Oncology, 2002. 20(22): p. 4420–4427.

    Article  PubMed  CAS  Google Scholar 

  86. O’connor, O.A., Wright, J., Moskowitz, C., Muzzy, J., Macgregor-Cortelli, B., Stubblefield, M., Straus, D., Portlock, C., Hamlin, P., Choi, E., Dumetrescu, O., Esseltine, D., Trehu, E., Adams, J., Schenkein, D. and Zelenetz, A.D., Phase ii clinical experience with the novel proteasome inhibitor bortezomib inpatients with indolent non-hodgkin’s lymphoma and mantle cell lymphoma. [see comment]. Journal of Clinical Oncology, 2005. 23(4): p. 676–684.

    Article  PubMed  CAS  Google Scholar 

  87. Belch, A., Kouroukis, C.T., Crump, M., Sehn, L., Gascoyne, R.D., Klasa, R.J., Jean, P. and Eisenhauer, E., Phase ii trial of bortezomib in mantle cell lymphoma [abstract]. Blood, 2004. 104: p. 608a.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Center for Lymphoma and Myeloma and Division of Hematology/Oncology, Weill Medical College of Cornell University and New York Presbyterian Hospital, New York, New York, USA

    Jia Ruan MD, PhD & John P. Leonard MD

Authors
  1. Jia Ruan MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. John P. Leonard MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Center for Lymphoma and Myeloma, Weill Medical College of Cornell University The New York Presbyterian Hospital, New York, New York

    John P. Leonard MD  & Morton Coleman MD  & 

Rights and permissions

Reprints and permissions

Copyright information

© 2006 Springer Science+Business Media, LLC

About this chapter

Cite this chapter

Ruan, J., Leonard, J.P. (2006). Mantle Cell Lymphoma: Current Concept in Biology and Treatment. In: Leonard, J.P., Coleman, M. (eds) Hodgkin’s and Non-Hodgkin’s Lymphoma. Cancer Treatment and Research, vol 131. Springer, Boston, MA. https://doi.org/10.1007/978-0-387-29346-2_5

Download citation

  • DOI: https://doi.org/10.1007/978-0-387-29346-2_5

  • Publisher Name: Springer, Boston, MA

  • Print ISBN: 978-0-387-29345-5

  • Online ISBN: 978-0-387-29346-2

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation